Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer|
|Citation:||International Journal of Radiation Oncology, Biology, Physics, 2013; 85(1):157-162|
|Michala Short, David Goldstein, Georgia Halkett, William Reece, Martin Borg, Yvonne Zissiadis, Andrew Kneebone, and Nigel Spry|
|Abstract:||<h4>Purpose</h4>To report quality of life (QOL) results for patients receiving chemoradiation therapy for pancreatic cancer.<h4>Methods and materials</h4>Eligible patients (n=41 locally advanced, n=22 postsurgery) entered the B9E-AY-S168 study and received 1 cycle of induction gemcitabine (1000 mg/m2 weekly ×3 with 1-week break) followed by 3-dimensional conformal radiation therapy (RT) (54 Gy locally advanced and 45 Gy postsurgery) and concomitant continuous-infusion 5-fluorouracil (5FU) (200 mg/m2/d throughout RT). After 4 weeks, patients received an additional 3 cycles of consolidation gemcitabine chemotherapy. Patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-PAN26 questionnaires at baseline, before RT/5FU, at end of RT/5FU, before consolidation gemcitabine, and at treatment completion.<h4>Results</h4>The patterns of change in global QOL scores differed between groups. In the locally advanced group global QOL scores were +13, +8, +3, and +1 compared with baseline before RT/5FU (P=.008), at end of RT/5FU, before consolidation gemcitabine, and at treatment completion, respectively. In the postsurgery group, global QOL scores were -3, +4, +15, and +17 compared with baseline at the same time points, with a significant improvement in global QOL before consolidation gemcitabine (P=.03). No significant declines in global QOL were reported by either cohort.<h4>Conclusions</h4>This study demonstrates that global QOL and associated function and symptom profiles for pancreatic chemoradiation therapy differ between locally advanced and postsurgery patients, likely owing to differences in underlying disease status. For both groups, the treatment protocol was well tolerated and did not have a negative impact on patients' global QOL.|
|Keywords:||Humans; Adenocarcinoma; Pancreatic Neoplasms; Fluorouracil; Deoxycytidine; Antimetabolites, Antineoplastic; Radiation-Sensitizing Agents; Treatment Outcome; Radiotherapy, Conformal; Prospective Studies; Quality of Life; Adult; Aged; Middle Aged; Female; Male; Chemoradiotherapy; Induction Chemotherapy; Surveys and Questionnaires|
|Rights:||© 2014 Elsevier Inc. All rights reserved.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.